Plain-English summary
Court unanimously reverses Fifth Circuit, narrows association standing and lifts injunctions on FDA actions on mifeprist
The Supreme Court unanimously reversed the Fifth Circuit, holding that the challengers lacked Article III standing to enjoin the FDA’s 2016 and 2021 actions regarding the abortion drug mifepristone. The case was remanded for further proceedings consistent with the decision.
Why this matters
The ruling tightens the rules for when organizations can sue to stop federal agency actions, requiring concrete, particularized injuries rather than hypothetical future harms to unnamed members. It also preserves the FDA’s regulatory decisions on mifepristone for now by undoing the lower court’s broad injunction, affecting access to the drug nationwide while further litigation proceeds.
Who may feel it
- Patients seeking mifepristone (the abortion pill)
- Doctors and clinics that prescribe or dispense mifepristone
- Pharmaceutical companies regulated by federal agencies
- Advocacy groups and associations that bring lawsuits against government actions
- Federal agencies facing legal challenges to their regulatory decisions
Key questions
- Can an association establish Article III standing by asserting that an unspecified member may be injured at some future time by a government action?